A phase I dose escalation trial of recombinant human macrophage colony-stimulating factor (rhM-CSF) in combination with conventional antifungal therapy was conducted in 24 marrow transplant recipients with invasive fungal infection. Daily doses ranged from 100 to 2,000 pg/m2/d. Toxicity, such as constitutional symptoms, directly ascribed to rhM-CSF was not observed; however, transient, dose-related thrombocytopenia was observed. Patients who received 2,000 pg/ mz/d of rhM-CSF had a mean reduction in platelet count of 61,000/mm3 during the rhM-CSF infusion period, which was significant when compared with patients who received lower doses of rhM-CSF (P = .008). Fourteen of the 16 patients who NVASIVE FUNGAL infections are a major cause of
I morbidity and mortality in patients with compromised host defense~.'.~ In bone marrow transplantation (BMT), they occur most frequently in patients before engraftment, in patients who fail to engraft, or in patients with acute graft-versus-host disease (GVHD) after e~~graftment.~'~ Approximately 16% of 1,500 patients transplanted from 1980 to 1986 in Seattle developed invasive fungal infections due to Candida, Aspergillus, or other fungi. Despite therapy with amphotericin and other antifungal agents, the mortality was greater than 80%. ' Macrophage colony-stimulating factor (M-CSF) is a heavily glycosylated, disulfide-linked homodimer first cloned and produced as a recombinant protein in 1985.8 Recombinant human M-CSF (rhM-CSF) stimulates survival, proliferation, and differentiation of progenitor cells in the monocyte/macrophage lineage in vitro.g M-CSF also enhances macrophage migration," expression of Fc receptors," cytotoxic activity of monocytes and macrophage^,"-'^ respiratory burst a~tivity,'~ and bacterial and fungal killing by macrophages in vitro.I5 M-CSF has also been shown to protect mice against a lethal candida albicans challenge.I6 Its toxicity in animal models has been limited to thrombocyt~penia."~'~ In patients who have received purified M-CSF, toxicity has been limited to bone pain. '8-21 Monocyte function, such as respiratory burst activity, migration, candida ingestion and degradation, was enhanced in 13 patients who received a single 2-hour intravenous dose of M-CSF, suggesting the need to evaluate the use of this factor in immunocompromised patients and patients with severe infection."
Therapy of invasive fungal infections with presently available antifungal agents is frequently not successful in severely immunocompromised patients. The present trial was initiated to assess the toxicity of rhM-CSF in conjunction with standard regimens of antifungal drugs in immunocompromised patients with invasive fungal infections before or after BMT.
MATERIALS AND METHODS
Patients with presumed or documented invasive fungal infection before or after BMT were eligible for the study. No exclusions were made for diagnosis, age, GVHD status,
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received rhM-CSF after undergoing allogeneic bone marrow transplantation had no change in the severity of graft-versushost disease (GVHD) while receiving rhM-CSF. One had an increase in the severity of GVHD and one had a decrease. There were no effects on neutrophil, monocyte, or lymphocyte counts. Six patients had resolution of their infections, 12 were not evaluable for response, and six did not respond. Ten patients survived 100 days after initiation of rhM-CSF and 14 died. Further trials with rhM-CSF to assess antifungal activity are indicated.
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or Karnofsky performance scores. The clinical characteristics of the 24 patients are given in Table 1 . Informed consent conforming to Federal Drug Administration and institutional review guidelines was required.
The diagnosis of documented invasive fungal infection required demonstration of organisms in histologic specimens, cultures of closed body fluids (ie, cerebral spinal fluid) or tissue biopsies, or radiologic evidence for invasive disease in the liver andlor spleen and the presence of at least a single positive blood culture. Patients with 2 2 positive blood cultures for Candida species or a single positive blood culture with another fungus were also considered to have invasive fungal infection for the purpose of this study.
Persistently febrile patients with fungi in bronchoalveolar lavage fluid without a positive blood culture, patients with fungi on gastrointestinal biopsy with only a single positive blood culture for Candida, or patients with suggestive radiologic studies without a positive blood culture were considered to have presumed infection and were also eligible to receive rhM-CSF. However, they were evaluated only for toxicity, but were not considered evaluable for response of infection to rhM-CSF. Patients in whom fungemia ceased before the initiation of rhM-CSF were also considered not evaluable for response to treatment. The infecting fungal organisms, the organs involved, and diagnostic modalities used to document infections are shown in Table 2 .
All patients were examined daily. Bone marrow aspirates and biopsies were performed before therapy to
Definition of invasive fingal infection.
Clinical monitoring. rule out malignancy where possible. Blood cultures were taken as clinically indicated. Blood chemistries and complete blood cell counts were performed daily. Follow-up evaluations of the fungal infections were performed by repeating the initial diagnostic procedures when possible or at autopsy.
NEMUNAITIS ET AL
The study was designed as a dose escalation trial in which patients were enrolled consecutively. All patients were simultaneously maintained on the best available antifungal therapy at maximally tolerated doses (Table 1) . rhM-CSF is a highly purified recombinant product produced in Escherichia coliu by Cetus Corporation (Emeryville, CA). The specific activity is 1 x lo7 Uimg. The dose range was 50 to 2,000 &mZ. rhM-CSF was administered in 100 mL of normal saline with 0.25% albumin by central venous catheter as a single 2-hour intravenous infusion daily for 7 days. If after 7 days there was no evidence for a clinical response and no toxicity, the dose was doubled and administered for an additional 7 days. Three dose escalations were allowed per patient. If a suggestion of response to rhM-CSF was noted (ie, clinical improvement or improvement in radiologic abnormalities), rhM-CSF was continued at the same dose until resolution of the fungal infection could be documented (histologically, if possible).
A patient was considered to have responded to treatment if there was complete resolution radiologically, histologically, and/or by follow-up cultures. If a patient did not have documented complete resolution of infection, this was considered as no response. If initial diagnostic procedures were not conclusive for
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diagnosis of fungal infection (ie, diagnosis by bronchoscopy or gastrointestinal biopsy) or if follow-up studies were not sufficient for evaluation of response, patients were considered not evaluable ( Table 2) .
Staristical analysis. Absolute and percent changes of blood cell counts were analyzed by the Wilcoxon signed-rank test.z4 Absolute and percent changes are defined as follows: Absolute change = counts post-M-CSF minus counts pre-M-CSF; % change = 100 x (absolute change divided by counts pre-M-CSF).
In cases of "0" absolute neutrophil count (ANC) or monocyte count, 1 was added to pre-M-CSF counts to avoid the division by 0. A relationship between maximum dose and change in blood cell counts was evaluated by regression analysis.=
RESULTS

Toxicity. rhM-CSF was well tolerated at all dose levels.
No constitutional symptoms were observed in patients while receiving rhM-CSF. One patient (unique patient number [UPN] 5497) had an increase in bilirubin during rhM-CSF administration. The autopsy results showed hepatic GVHD and thus the etiology of the increase in bilirubin was attributed to GVHD.
One patient (UPN 5497) had an increase in grade of GVHD from grade I to grade I11 after starting rhM-CSF For personal use only. on October 23, 2017. by guest www.bloodjournal.org From autopsy.
Open liver biopsy showed no fungus.
Resolution of hypodense lesions and negative autopsy. Clinically without evidence of infection, but hypodense lesions persist by CT scan. Clinically without evidence of infection, but persistent hypodense lesions by CT scan. Blood cultures became negative, but candida was isolated from lung, spleen, and liver by autopsy. Skin nodules decreased in size and number, but did not resolve before death from CMV pneumonia. Nodules increased in size when rhM-CSF was discontinued before death. Aspergillus present in the brain at autopsy.
Fungal organisms identified by needle aspirate of liver after therapy with rhM-CSF. Treatment was reinstituted. Significant clinical and radiologic improvement, but initial invasive fungal infection of the lung was not confirmed by biopsy and the positive blood culture was 6 days before rhM-CSF was started. Only bronchoscopic diagnosis of initial infection.
The last positive blood culture was 12 days before rhM-CSF was started. Significant clinical and radiologic improvement, but fungal infection of the lung was diagnosed by bronchoscopy only. Cerebral spinal fluid cultures were negative after starting rhM-CSF, but blood cultures were negative 3 weeks before rhM-CSF. Skin nodules completely resolved, but skin lesions were already improving and the fever resolved 24 hours before treatment with rhM-CSF. Lung nodules resolved by CT scan, but no biopsy was performed. The blood culture was later considered a contaminant. No organisms identified by autopsy, but cannot rule out the possibility that the only initial fungal lesion was removed by pretreatment surgery. Blood cultures became negative while on rhM-CSF; however, clinical improvement was not observed and autopsy was not performed. Blood cultures became negative while on rhM-CSF; however, the Hickman catheter was removed before rhM-CSF was started. Therefore, the response may have been related to the pulling out of the Hickman catheter. Skin lesions significantly decreased in size and number, but lung infiltrateshodules did not resolve.
Abbreviations: CNS, central nervous system; CSF, cerebral spinal fluid. *Infection status on survival day: R. resolution; NR, no resolution; NE, not evaluable. tHistologic identification only.
For (-) , not alive.
of last contact (status) is the number of days after the initiation of rhM-CSF therapy in which the patient was examined or contacted by phone: (+),still alive;
( Table 3) . Otherwise, there were no other effects on the severity of GVHD during the rhM-CSF infusion course (n = 14). Patient UPN 4945, who received a two-antigen mismatched transplant, developed hyperacute GVHD 48 hours after rhM-CSF was discontinued. Two patients (UPNs 5402 and 5047) had an increase in severity of GVHD more than 1 week after discontinuation of rhM-CSF.
The white blood cell count (WBC), ANC, monocyte count, lymphocyte count, and platelet count before rhM-CSF and on the last day of rhM-CSF therapy are shown in Table 4 . No significant change in WBC, ANC, monocyte count, or lymphocyte count was detected the day of completion of rhM-CSF therapy (Table  4) or at weekly intervals during rhM-CSF therapy. Thrombocytopenia was observed and appeared to be related to the maximum dose of rhM-CSF and not the duration of treatment or time of administration before or after BMT (see Fig 1, P = .005) . Patients who received 2,000 pg/m*/d of rhM-CSF had a mean reduction in platelet count of 61,000/mm3 during the rhM-CSF infusion period, which was significant when compared with patients who received lower doses of rhM-CSF (P = .008). The median decrease in platelet count of all patients was 30,000/mm3 ( Table 4) . The thrombocytopenia did not contribute to morbidity or mortality in any patient. Nevertheless, in view of the relationship of thrombocytopenia to dose of rhM-CSF, further dose escalation was not done. There was no significant change in bone marrow cellularity or megakaryo-
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cyte cellularity before or after treatment with rhM-CSF (data not shown) and no patient had relapse of their underlying malignancy while receiving rhM-CSF.
Twelve patients were considered evaluable for response of fungal infection in association with rhM-CSF administration and 12 were considered not evaluable. Among the 12 evaluable patients, six responded with documented clearing of their infection ( Table 2) . Three (UPNs 5143,5514, and 5552) have survived 100 days after initiation of therapy with rhM-CSF. One (UPN 4945) died of GVHD-related complications, one (UPN 5598) died of CMV pneumonia, and one (UPN 5049) died of pneumonitis ( Table 3 ). The other six evaluable patients were considered to have not responded to therapy with rhM-CSF. Of these non-responders, three are surviving. Two (UPNs 5238 and 5640) have no clinical evidence of infection, but have persistent lesions on computerized tomography (CT) scan and one (UPN 5435) had persistent fungal infection documented by follow-up biopsy (Tables 2 and 3) . The other three patients died within 100 days after initiation of rhM-CSF. In two, death was associated with fungal infection (UPNs 5415 and 5240) and in the other (UPN 4647) with cytomegalovirus (CMV) pneumonia (Tables 2 and 3) .
Six patients who were initially felt not to be BMT candidates because of lack of response to amphotericin and progressive fungal disease received rhM-CSF before BMT (Tables 1 and 2) . Five of these patients subsequently underwent allogeneic BMT. One patient (UPN 5226)
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effects.
developed progressive pulmonary infiltrates after a needle biopsy and died before BMT. One patient (UPN 5435) required reinstitution of rhM-CSF and amphotericin B for recurrent infection after BMT. Another patient (UPN 5640) received rhM-CSF before conditioning for BMT and later after marrow infusion. Decreased, but persistent CT abnormalities remained after completion of rhM-CSF treatment and he was considered a non-responder. However, he remains without clinical evidence of infection off of all antifungal therapy. Three other patients had resolution of infection (UPNs 5514, 5552, and 5598) ( Table 2 ). Four of the five patients who underwent BMT survived 100 days after initiation of rhM-CSF therapy and one patient (UPN 5598) died 59 days after BMT ( Table 3) . Twelve patients with Karnofsky performance scores less than or equal to 30 received rhM-CSF after BMT ( Table 3) ,,l,,,.,..,,,,,,,,....,,..l....l.. (Tables 1 and 2 ). Two of the 12 patients (UPNs 4991 and 5237) survived 100 days after initiation of rhM-CSF; one (UPN 4991) had persistent pulmonary nodules by CT scan and the other (UPN 5237) had no evidence of fungal infection. The remaining 10 patients died within 100 days after starting rhM-CSF (Tables 2 and 3) .
Six patients with Karnofsky performance scores 2 40% received rhM-CSF after BMT; One (UPN 5143) had resolution of infection, four (UPNs 5402, 5452, 5407, and 5564) were not evaluable, and one (UPN 5238) had no clinical evidence of infection, but did not have complete resolution of lesions on CT scan and, therefore, was considered a non-responder ( Table 2 ). Four of the six patients (UPNs 5143, 5452, 5238, and 5564) survived 100 days after initiation of rhM-CSF. The other two (UPNs 5402 and 5407) died of GVHD-related complications after discontinuation of rhM-CSF (Table 3) .
DISCUSSION
In this study, rhM-CSF at doses up to 2,000 &mZ/d was well tolerated in patients with invasive fungal infection before or after BMT. However, because thrombocytopenia developed in 12 of 13 patients who received the 2,000 pgim2/d dose of rhM-CSF, further dose escalation was discontinued. This result was consistent with prior animal trials in which reduced platelet survival and thrombocytopenia was observed at higher doses. Animal trials also showed that rhM-CSF at high doses induces modest neutrophilia, monocytosis and lympho~ytopenia.'~"~ Purified urinary M-CSF has been administered to neutropenic patients and patients after allogeneic or autologous BMT in phase 1/11 trials to evaluate toxicity. It was well tolerated. Mild neutrophilia was observed and there were no significant adverse effects on platelet counts or GVHD. [19] [20] [21] In the present trial, no change in neutrophil, monocyte, or lymphocyte counts was observed, although it was difficult to evaluate the effect of rhM-CSF on WBC because the starting time was variable in relation to the day of marrow infusion. However, thrombocytopenia was observed in all but one of the patients receiving the 2,000 pgimz/d dose. The etiology of the thrombocytopenia is unknown, although studies in animals suggest that enhanced function of splenic phagocytes may relate to the thrombocytopenia.'* It is interesting that three of the six patients who responded to rhM-CSF received the 2,000 pgim2/d dose, suggesting that there may be a narrow therapeutic window with the use of rhM-CSF in BMT patients with low megakaryocyte reserves. An influence of infection, interaction with its treatment, or other factors in these patients with complex medical problems may have also contributed to thrombocytopenia.
A concern about the use of rhM-CSF after allogeneic BMT is that it might induce or exacerbate GVHD. rhM-CSF stimulates production of interleukin-1 (IL-1)z6 and tumor necrosis factor (TNF),27 which may affect severity of GVHD. One of the 16 patients who received rhM-CSF after allogeneic BMT had an increase in the severity of GVHD while receiving rhM-CSF and one had an increase in severity of GVHD 48 hours after discontinuation of rhM-CSF. Otherwise, no consistent effects on GVHD were observed.
To minimize responses that may not be related to the administration of rhM-CSF and because of the relatively short follow-up, the definition of response used in this study was stringent. However, the clinical courses observed in some patients when rhM-CSF was added to conventional antifungal therapy were encouraging. For example, one patient (UPN 5514) had invasive aspergillus fumigatus of his sinus cavities and azotemia secondary to amphotericin therapy. Progressive fungal infection with new pulmonary nodules occurred after 3.5 g of amphotericin. His daily amphotericin dose was reduced to 0.5 m a g and he was started on rhM-CSF. Radiologic studies that were confirmed by open pulmonary and sinus biopsies showed resolution of fungal infection. He subsequently underwent an allogeneic BMT from an unrelated donor and remains alive without recurrence of his original infection. Another patient (UPN 5552) had multiple, expanding liver abscesses after therapy with 2 g of amphotericin. Open liver biopsy before BMT showed the continued presence of candida species. Daily amphotericin (0.5 mgkg) was continued and rhM-CSF was started. Radiologic studies that were confirmed by repeat open liver biopsy showed resolution of fungal infection. He subsequently underwent allogeneic BMT from a sibling donor and remains alive without recurrence of fungal infection. Overall, 39% of the patients with documented infection and 50% of patients with presumed infection survived 100 days after initiation of treatment with rhM-CSF. Because most patients with a poor performance status died of causes other than fungal infection, earlier institution of rhM-CSF therapy in the relation to the diagnosis of infection may be necessary to have a greater impact on survival. Historically comparable patients with invasive fungal disease who did not receive rhM-CSF had a survival of under 20%.7 A randomized, controlled trial to better define rhM-CSF toxicity and to test its efficacy in the treatment of invasive fungal disease appears warranted.
